FDA Approves First Genetically Modified Food-Producing Animal

by King & Spalding

On November 19, 2015, the United States Food and Drug Administration (FDA) approved a new animal drug application (NADA) that authorizes the marketing of the AquAdvantage Salmon, a genetically modified Atlantic salmon. In approving the NADA, FDA concluded, among other things, that the AquAdvantage Salmon is as safe to eat as any non-genetically modified Atlantic salmon. King & Spalding has represented the sponsor of the NADA, AquaBounty Technologies, Inc., since 2009.

Since the early 1980s, FDA has been a leader in developing meaningful scientific criteria and employing a flexible interpretation of the statutory requirements to ensure that the use of biotechnology in producing FDA-regulated products does not pose a risk to consumers. In regulating biotechnology products, FDA has not sought any additional statutory authority and has persuasively taken the position that its existing statutory authorities for regulating drugs, medical devices, food, and animal drugs are sufficient to ensure the safe and appropriate use of any such product derived from biotechnology.1

Over the years, FDA has successfully overseen and regulated the marketing of numerous genetically modified drugs and plant foods. Not until now, however, has it authorized the marketing of a genetically modified animal. In large part, this gap may be attributed to the rigor FDA has applied in regulating the use of biotechnology in this context. FDA defines “genetically engineered animals” as those animals modified by Ribosomal DNA (rDNA) techniques, including all progeny that contain the modification. In FDA’s view, the term “genetically engineered animal” can refer both to animals with a heritable rDNA construct and to an animal with a non-heritable rDNA construct (e.g., a construct intended as therapy for a disease in that animal).  FDA regulates modified animals under the new animal drug provisions of the Federal Food, Drug, and Cosmetic Act. In light of the fact that Section 201(g) of the Act defines “drugs,” in part, as “articles (other than food) intended to affect the structure or any function of the body of man or other animals,” FDA has concluded that any rDNA construct in the resulting modified animal meets this definition. Thus, the modified animal itself is not a drug, the animal is just “along for the ride” with the rDNA construct being the “drug.”

With respect to food-producing animals, the safety of the food derived from a modified animal must be evaluated just as the safety of any food-producing animal on the receiving end of a new animal drug must be evaluated. The food safety evaluation FDA employs focuses on whether the food from the modified animal poses any risk to humans or animals consuming edible products from the modified animal compared to the edible products from appropriate non-transgenic comparators. FDA divides the food safety risk questions into two overall categories. First, it asks whether there is any direct toxicity, including allergenicity, associated with the expression product of the construct or components of the construct. Second, FDA focuses on any potential indirect toxicity associated with both the transgene and its expression product (i.e., will the expression of the transgene affect the physiological processes and the resulting animal so that unintended food consumption hazards are created or existing food consumption risks are exacerbated or increased). Natural adverse outcomes are identified by determining whether there are any biologically relevant changes to physiology in the animal, and whether reasons for toxicological concern are suggested by any biologically relevant changes in the composition of edible products from the modified animal compared with those from the appropriate non-transgenic comparator.

AquaBounty’s NADA was before FDA for nearly 20 years. The genetic modifications involved are both straightforward and limited: the insertion of a gene from the Pacific Chinook salmon and a gene from the Ocean Pout (an eel-like fish). The effect, too, is straightforward: the modified Atlantic salmon reaches market weight in half the time of an unmodified Atlantic salmon. The fish will be raised in land-based facilities (as opposed to off-shore net pens or cages) outside of the United States. The modified salmon are all female, and are all sterile. The facilities in which the fish will be raised are secure and have multiple redundant forms of physical containment that have been verified and validated by FDA.

With respect to the labeling of marketed AquAdvantage Salmon, FDA has determined that the term “Atlantic salmon” is the appropriate common or usual name of the food. FDA reached this conclusion based on the fact that the AquAdvantage Salmon does not differ materially or significantly from its counterpart—non-modified farm-raised Atlantic salmon. Moreover, FDA has concluded that the modified salmon is as safe and nutritious as its non-modified counterpart. Accordingly, FDA has concluded that there is no legal basis to require that the AquAdvantage Salmon be labeled as “modified,” “genetically engineered,” “GMO,” or any similar appellation. 

The approval is controversial. Consumer and environmental groups have made no secret of their distrust of the technology, and of the agency. The key factor underlying these concerns, however, is likely not with the AquAdvantage Salmon, the safety of which is firmly established, but rather with the fact that now, with this approval, there is a clear signal that the new animal drug approval system, complicated as it is, works and as a result, an array of other authorizations for modified food-producing animals may soon follow.

Author: Frederick H. Degnan, Partner, Washington, D.C., +1 202 626 3742, fdegnan@kslaw.com.

1 See, for example, State of Policy for Regulating Products of Biotechnology, 51 Fed. Reg. 23309 (June 26, 1986).

Written by:

King & Spalding

King & Spalding on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.